Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)

RSS

clopidogrel / acetylsalicylic acid

Authorised
This medicine is authorised for use in the European Union.

Overview

This document is a summary of the European Public Assessment Report (EPAR) for Clopidogrel/Acetylsalicylic acid Zentiva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel/Acetylsalicylic acid Zentiva.

This EPAR was last updated on 13/11/2019

Authorisation details

Product details
Name
Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
Agency product number
EMEA/H/C/001144
Active substance
  • clopidogrel
  • acetylsalicylic acid
International non-proprietary name (INN) or common name
clopidogrel / acetylsalicylic acid
Therapeutic area (MeSH)
  • Acute Coronary Syndrome
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01AC30
Publication details
Marketing-authorisation holder
Sanofi-Aventis Groupe
Revision
22
Date of issue of marketing authorisation valid throughout the European Union
14/03/2010
Contact address
54 rue La Boétie
F-75008 Paris
France

Product information

19/09/2019 Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover) - EMEA/H/C/001144 - WS/1665

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

  • Acute Coronary Syndrome
  • Myocardial Infarction

Assessment history

How useful was this page?

Add your rating